Tag
NYSE: NVO
- Novo Nordisk seeks US and EU approval for sickle cell drug etavopivat
- Eli Lilly raises revenue outlook to US$91B to US$92B
- Zealand Pharma reports up to 9.2% weight loss in Phase 2 diabetes trial
- Viking Therapeutics begins oral VK2735 maintenance trial in obesity
- Novo Nordisk A/S says FDA extends denecimig review over facility remediation
- Novo Nordisk reports normal liver fat in 23 of 26 Wegovy users
- Eli Lilly and Company wins FDA approval for weekly Onswik insulin
- Nanexa AB shares jump 105% on Novo Nordisk drug-delivery licence
- Eli Lilly says Foundayo draws one‑third of new GLP‑1 pill patients
- Health Canada approves Zepbound for obstructive sleep apnea in adults with obesity
- Akero Therapeutics nearly doubles stock price on positive clinical studies